Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Dangerous Interaction Between The Antidepressant Fluvoxamine And The Muscle Relaxant Tizanidine

06.04.2004


Researchers from Finland have found that the antidepressant drug fluvoxamine (brand names Fevarin, Faverin, Luvox etc.) drastically increases the concentrations of tizanidine (Sirdalud, Zanaflex) in blood.



Concomitant use of fluvoxamine and tizanidine results in severe and prolonged decrease in blood pressure and greatly enhanced central nervous system effects. This previously unrecognised interaction can be dangerous, particularly in elderly patients, and the concomitant use of the two agents must be avoided. Both fluvoxamine and tizanidine have been in wide clinical use for more than 10 years.

The concentrations of tizanidine in blood were increased on average 33-fold by fluvoxamine in a carefully controlled study in healthy volunteer subjects. The volunteers ingested the usual 100-mg dose of fluvoxamine or placebo daily for 4 days, and then a single 4-mg dose of tizanidine. The interaction was observed in each of the ten subjects; the smallest increase in tizanidine concentration by fluvoxamine was 14-fold, the greatest increase was 103-fold!


The effects of tizanidine were much stronger during fluvoxamine treatment than during placebo treatment. In particular, the decrease in systolic blood pressure, to the level of 80-mm Hg or even less, was an alarming finding. Such grave hypotension is dangerous, eg in elderly subjects and in patients who have heart problems. Also the central nervous system effects of tizanidine were greatly enhanced by fluvoxamine: all ten subjects were somnolent and dizzy for 3 to 6 hours after tizanidine intake.

Both tizanidine and fluvoxamine are widely used drugs in many countries, including USA. In Finland (population 5 200 000) about 10 000 patients are using tizanidine daily, and about 5000 patients are using fluvoxamine daily. Different types of acute and chronic pain syndromes are common in the patients with depression. Therefore, it is likely that fluvoxamine and tizanidine can be coadministrered frequently, if the risk of the interaction is not recognised by clinicians.

The interaction resulted from inhibition of the liver metabolism of tizanidine by fluvoxamine. Further studies are being carried out to characterise the potential interactions of tizanidine with other drugs.

The study was conducted at the Department of Clinical Pharmacology, University of Helsinki, by an independent group of researchers led by Professor Pertti J Neuvonen, MD, PhD, and Dr. Janne T Backman, MD, PhD. The study was published in the April issue of the scientific journal Clinical Pharmacology & Therapeutics.

Paivi Lehtinen | alfa
Further information:
http://www.helsinki.fi/

More articles from Health and Medicine:

nachricht A new approach to targeting cancer cells
20.05.2019 | University of California - Riverside

nachricht Radioisotope couple for tumor diagnosis and therapy
14.05.2019 | Kanazawa University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Self-repairing batteries

UTokyo engineers develop a way to create high-capacity long-life batteries

Engineers at the University of Tokyo continually pioneer new ways to improve battery technology. Professor Atsuo Yamada and his team recently developed a...

Im Focus: Quantum Cloud Computing with Self-Check

With a quantum coprocessor in the cloud, physicists from Innsbruck, Austria, open the door to the simulation of previously unsolvable problems in chemistry, materials research or high-energy physics. The research groups led by Rainer Blatt and Peter Zoller report in the journal Nature how they simulated particle physics phenomena on 20 quantum bits and how the quantum simulator self-verified the result for the first time.

Many scientists are currently working on investigating how quantum advantage can be exploited on hardware already available today. Three years ago, physicists...

Im Focus: Accelerating quantum technologies with materials processing at the atomic scale

'Quantum technologies' utilise the unique phenomena of quantum superposition and entanglement to encode and process information, with potentially profound benefits to a wide range of information technologies from communications to sensing and computing.

However a major challenge in developing these technologies is that the quantum phenomena are very fragile, and only a handful of physical systems have been...

Im Focus: A step towards probabilistic computing

Working group led by physicist Professor Ulrich Nowak at the University of Konstanz, in collaboration with a team of physicists from Johannes Gutenberg University Mainz, demonstrates how skyrmions can be used for the computer concepts of the future

When it comes to performing a calculation destined to arrive at an exact result, humans are hopelessly inferior to the computer. In other areas, humans are...

Im Focus: Recording embryonic development

Scientists develop a molecular recording tool that enables in vivo lineage tracing of embryonic cells

The beginning of new life starts with a fascinating process: A single cell gives rise to progenitor cells that eventually differentiate into the three germ...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

SEMANTiCS 2019 brings together industry leaders and data scientists in Karlsruhe

29.04.2019 | Event News

Revered mathematicians and computer scientists converge with 200 young researchers in Heidelberg!

17.04.2019 | Event News

First dust conference in the Central Asian part of the earth’s dust belt

15.04.2019 | Event News

 
Latest News

Synthesis of helical ladder polymers

21.05.2019 | Materials Sciences

Ultra-thin superlattices from gold nanoparticles for nanophotonics

21.05.2019 | Materials Sciences

Chaperones keep the tumor suppressor protein p53 in check: How molecular escorts help prevent cancer

21.05.2019 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>